Skip to main content

Alumni Achievement Award

Dale Kempf, PHD ’82 LAS

Dale Kempf, PHD ’82 LAS Dale is a distinguished research fellow at research biopharmaceutical company AbbVie where he coordinates its Neglected Diseases Program. He has nearly 35 years of pharmaceutical research and development experience, mostly in antiviral and infectious diseases. He is a co-inventor of AbbVie’s HIV protease inhibitors Norvir™ and Kaletra™. Kempf co-directed AbbVie’s hepatitis C discovery program leading to the development of Viekira Pak™ and Mavyret™. He has published widely in areas of medicinal chemistry, pharmacology and drug resistance, and has received several awards, including the 1997 Intellectual Property Owners Association National Inventor of the Year Award, the 1999 Pharmaceutical Research and Manufacturers of America Discoverers Award, the 2003 American Chemical Society Heroes of Chemistry Award, the 2010 David Berry HIV DART Achievement Award, and the 2014 Yau Yuan Award for Excellence.

Laura E. Niklason, ’83 LAS, ’83 LAS

Laura E. Niklason, ’83 LAS, ’83 LAS Laura is a professor of anesthesiology and biomedical engineering at Yale University. Her research focuses on vascular and lung engineering. In 2004, she co-founded Humacyte, a world leader in tissue engineering that has gained international attention for its work in developing a bioengineered human acellular vessel (HAV) that could replace the blood vessel or create new vascular access without requiring a patient’s cells or tissue. Laura Niklason was cited by Time for creating one of the 50 Best Inventions of 2010 (an engineered lung), inducted into the National Academy of Inventors in 2014, elected to the National Academy of Medicine in 2015, named as a 2016 Alumni Achievement Award recipient for the College of Liberal Arts and Sciences, inducted into Women in Technology Hall of Fame in 2017, and named by Fortune magazine in 2017 as one of 34 Leaders Who are Changing Health Care. Humacyte received accolades in 2011 from Popular Mechanics for development of an “off-the-shelf” tissue engineered vascular graft.